Page 1

AlzeCure PRESS RELEASE 18 September 2026 12:30:00 CEST AlzeCure Pharma publishes updated company presentation following the Eli Lilly and QuantumCell agreements AlzeCure Pharma AB ( " AlzeCure " or " The Company " ) ( FN STO : ALZCUR ) , which develops small- molecule drug candidates for CNS diseases with a focus on Alzheimer's disease and pain , today announced that an updated company presentation in English is now available . In the presentation , CEO Martin Jönsson provides an updated view of the company following the recently signed collaboration and outlicensing agreements with US - based Eli Lilly and Denmark - based QuantumCell ApS , both relating to AlzeCure's Alzheimer's programs . The presentation is in English , produced by FinWire , and available on demand via the link below : https://www.youtube.com/watch?v=Hw6ObMZdHdM&feature=youtu.be For more information , please contact Martin Jönsson , CEO Tel : +46 ( 0 ) 70 786 94 43 martin.jonsson@alzecurepharma.com About AlzeCure Pharma AB ( publ ) AlzeCure® is a Swedish biotech company developing new , innovative drug therapies for severe diseases and conditions affecting the central nervous system , such as Alzheimer's disease and pain - indications where available treatment options today are very limited . The company is listed on Nasdaq First North Premier Growth Market and is developing several drug candidates in parallel based on three research platforms : NeuroRestoreⓇ , AlzstatinⓇ and Painless . AlzeCure has recently signed collaboration and outlicensing agreements with Eli Lilly on the Alzstatin platform , and with QuantumCell ApS on the NeuroRestore platform . FNCA Sweden AB is the company's Certified Adviser . For more information , visit www.alzecurepharma.com Image Attachments Martin Jönsson CEO AlzeCure Pharma Attachments AlzeCure Pharma publishes updated company presentation following the Eli Lilly and QuantumCell agreements AlzeCure Pharma • Hälsovägen 7 SE - 141 57 Huddinge